ArticlePloS one2025
Accuracy of the Modified Finnish Diabetes Risk Score (Modified FINDRISC) for detecting metabolic syndrome: Findings from the Indonesian national health survey.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Predicting Metabolic Syndrome Using Supervised Machine Learning: A Multivariate Parameter Approach.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study evaluated the diagnostic accuracy of the Modified Finnish Diabetes Risk Score (Modified FINDRISC) for detecting individuals with metabolic syndrome in Indonesia.
methodsA dataset from the 2018 Indonesian National Basic Health Survey was analysed, and cases of metabolic syndrome were identified in accordance with both National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) and International Diabetes Federation (IDF) guidelines. Diagnostic accuracy of the Modified FINDRISC tool was evaluated using the Area Under the Receiver Operating Characteristic (AUC) curve, while optimal cut-off scores were determined by Youden's Index.
resultsFrom 25,432 participants, the mean and standard deviation of the Modified FINDRISC score was 5.7 (SD 4.1). The prevalence of metabolic syndrome was 32.1% and 24.8% based on NCEP-ATP III and IDF criteria, respectively. Based on NCEP-ATP III criteria alone, the AUC of the Modified FINDRISC was 80.9% (80.3%-81.5%) with 74.0% sensitivity and 75.5% specificity. Similarly, based on IDF criteria, AUC was 88.9% (88.5%-89.3%) with 89.8% sensitivity and 75.8% specificity. The optimal cut-off score was 6 for both criteria, with 41.2% of the total participants above the cut-off who would require further confirmation tests.
conclusionMetabolic syndrome is prevalent in Indonesia, and the Modified FINDRISC tool offers good diagnostic accuracy for detecting such cases. Utilising Modified FINDRISC as a first-instance screening modality will reduce the number of people requiring further confirmation tests. Modified FINDRISC has the potential for use in daily clinical practice, and the cost-effectiveness of Modified FINDRISC should be further evaluated.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.